Patents Assigned to Emergent Product Development of Gaithersburg, Inc.
-
Publication number: 20240174619Abstract: This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.Type: ApplicationFiled: March 2, 2022Publication date: May 30, 2024Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Anthony M. TRESTON, Kelly Lyn WARFIELD
-
Publication number: 20240082198Abstract: This disclosure describes a composition comprising an alkyl nitrite, such as isoamyl nitrite, and an effective amount of at least one stabilizing compound, such as one or more of vitamins K1, K2, and K3.Type: ApplicationFiled: September 30, 2021Publication date: March 14, 2024Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Daniel Cope HILL, Anthony M. TRESTON
-
Patent number: 10517865Abstract: Disclosed herein are compounds of Formula I wherein R1, R2, X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.Type: GrantFiled: April 13, 2018Date of Patent: December 31, 2019Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Patrick Roussel, Jutta Heim, Peter Schneider, Christian Bartels, Yaoquan Liu, Glenn Dale, Daniel Milligan
-
Patent number: 10357559Abstract: Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.Type: GrantFiled: December 23, 2014Date of Patent: July 23, 2019Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Jee Look, Christian Fernando Ruiz, Aaron Paul Miles, Richard William Welch
-
Publication number: 20190105367Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.Type: ApplicationFiled: November 13, 2018Publication date: April 11, 2019Applicant: Emergent Product Development Gaithersburg Inc.Inventors: Jutta HEIM, Peter SCHNEIDER, Patrick ROUSSEL, Daniel MILLIGAN, Christian BARTELS, Glenn DALE
-
Patent number: 10155021Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.Type: GrantFiled: June 23, 2016Date of Patent: December 18, 2018Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
-
Publication number: 20160324957Abstract: Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.Type: ApplicationFiled: December 23, 2014Publication date: November 10, 2016Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Jee LOOK, Christian Fernando RUIZ, Aaron Paul MILES, Richard William WELCH
-
Patent number: 9403818Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.Type: GrantFiled: January 31, 2012Date of Patent: August 2, 2016Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
-
Publication number: 20150335752Abstract: Formulations of vaccine antigen, such as anthrax protective antigen, are provided that are stable after undergoing freeze and thaw conditions. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.Type: ApplicationFiled: June 25, 2013Publication date: November 26, 2015Applicant: Emergent Product Development Gaithersburg Inc.Inventors: Jee Look, Christian Fernando Ruiz, Aaron Paul Miles, Richard William Welch
-
Publication number: 20130115234Abstract: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.Type: ApplicationFiled: March 28, 2011Publication date: May 9, 2013Applicant: Emergent Product Development Gaithersburg,Inc.Inventors: Tina Guina, Michael Lacy, Mario Skiadopoulos, Nutan Mytle
-
Patent number: 7914795Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.Type: GrantFiled: August 14, 2009Date of Patent: March 29, 2011Assignee: Emergent Product Development Gaithersburg, Inc.Inventors: Kenneth Tucker, Laura Plosila, Ulrich F. Tillman
-
Publication number: 20110027321Abstract: The present invention provides vaccine compositions useful in prevention and treatment of Chlamydia sp. (e.g., C. trachomatis or C. pneumoniae) infection. Provided are polypeptide vaccine antigens comprising Chlamydia HtrA-derived sequences, including epitopic fragments, analogs, derivatives, and variants. Also provided are a method for inducing an immune response to a subject against Chlamydia infection, a method for preventing Chlamydia infection, or a method for treating a disease or symptom caused by or resulting from infection with Chlamydia, for instance, C. trachomatis or C. pneumoniae. In one embodiment, the present invention is drawn to C. trachomatis HtrA, which induces a cellular immune response and imparts partial protective immunity in vivo.Type: ApplicationFiled: May 23, 2008Publication date: February 3, 2011Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Hang Lu, Gary S. Nabors, W. James Jackson, Xuan Z. Ding, Steven F. Roberts
-
Patent number: 7851609Abstract: The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrp, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.Type: GrantFiled: July 20, 2007Date of Patent: December 14, 2010Assignee: Emergent Product Development Gaithersburg Inc.Inventor: W. James Jackson
-
Publication number: 20100310593Abstract: The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Chlamydia infection. The present invention is also directed toward an isolated nucleic acid encoding a polypeptide comprising at least 70% identity to any one of SEQ ID NOS: 2, 11, 13, 19, or 21, wherein the polypeptide is soluble in the absence of denaturing agents. In some aspects of the invention, the polynucleotide is codon-optimized. In some embodiments, the present invention is related to the polypeptide encoded by the polynucleotide of the invention. Administration of polypeptides of the present invention can be used as a method to treat or prevent a Chlamydia infection in an animal in need thereof.Type: ApplicationFiled: June 16, 2008Publication date: December 9, 2010Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: So-ching Brazer, James Adam Crawford, Chunghee Lee, Sukjoon Park, W. James Jackson, Michael Joseph Lacy, Hang Lu
-
Patent number: 7846451Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.Type: GrantFiled: December 21, 2007Date of Patent: December 7, 2010Assignee: Emergent Product Development Gaithersburg, Inc.Inventors: Kenneth Tucker, Ulrich F. Tillman
-
Patent number: 7803388Abstract: The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrom, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.Type: GrantFiled: July 20, 2007Date of Patent: September 28, 2010Assignee: Emergent Product Development Gaithersburg, Inc.Inventor: W. James Jackson
-
Patent number: 7731980Abstract: The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrp, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.Type: GrantFiled: September 28, 2001Date of Patent: June 8, 2010Assignee: Emergent Product Development Gaithersburg Inc.Inventor: W. James Jackson
-
Patent number: 7655246Abstract: A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.Type: GrantFiled: September 1, 2004Date of Patent: February 2, 2010Assignee: Emergent Product Development Gaithersburg Inc.Inventors: W. James Jackson, John L. Pace
-
Patent number: D957624Type: GrantFiled: September 8, 2020Date of Patent: July 12, 2022Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Gaëtan Painchaud, Marc Todesco
-
Patent number: D965767Type: GrantFiled: February 25, 2021Date of Patent: October 4, 2022Assignee: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventors: Johnathan Stuart Coursey, Girum Yemane-Tekeste, Kathy K. Smith